- Home
- CNTX vs EQ Comparison
CNTX vs EQ Comparison
Compare CNTX & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- EQ
- Stock Information
- Founded
- CNTX 2015
- EQ 2017
- Country
- CNTX United States
- EQ United States
- Employees
- CNTX N/A
- EQ N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- CNTX Health Care
- EQ Health Care
- Exchange
- CNTX Nasdaq
- EQ Nasdaq
- Market Cap
- CNTX 75.6M
- EQ 85.1M
- IPO Year
- CNTX 2021
- EQ 2018
- Fundamental
- Price
- CNTX $1.26
- EQ $1.41
- Analyst Decision
- CNTX Strong Buy
- EQ Hold
- Analyst Count
- CNTX 7
- EQ 2
- Target Price
- CNTX $5.20
- EQ $1.00
- AVG Volume (30 Days)
- CNTX 500.2K
- EQ 667.8K
- Earning Date
- CNTX 11-10-2025
- EQ 11-12-2025
- Dividend Yield
- CNTX N/A
- EQ N/A
- EPS Growth
- CNTX N/A
- EQ N/A
- EPS
- CNTX N/A
- EQ N/A
- Revenue
- CNTX N/A
- EQ $16,553,000.00
- Revenue This Year
- CNTX N/A
- EQ N/A
- Revenue Next Year
- CNTX N/A
- EQ N/A
- P/E Ratio
- CNTX N/A
- EQ N/A
- Revenue Growth
- CNTX N/A
- EQ N/A
- 52 Week Low
- CNTX $0.49
- EQ $0.27
- 52 Week High
- CNTX $2.46
- EQ $2.35
- Technical
- Relative Strength Index (RSI)
- CNTX 56.22
- EQ 50.21
- Support Level
- CNTX $1.19
- EQ $1.25
- Resistance Level
- CNTX $1.50
- EQ $1.55
- Average True Range (ATR)
- CNTX 0.15
- EQ 0.12
- MACD
- CNTX -0.02
- EQ 0.00
- Stochastic Oscillator
- CNTX 39.78
- EQ 51.24
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.